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013.01.00Abstract Aim of the work: This study aimed to investigate serum levels of vitamin D in patients
with Behc¸et’s disease (BD) and to evaluate their relationship to disease activity as well as different
disease measures.
Patients and methods: Forty-two patients with BD were enrolled into this study. These patients
were subjected to detailed history taking, thorough clinical examination including assessment of dis-
ease activity according to Behc¸et’s Disease Current Activity Form (BDCAF) score and performed
laboratory investigations including erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), serum calcium, serum phosphorus and serum alkaline phosphatase. Serum 25-hydroxyvitamin
D (vitamin D) levels were determined using Enzyme-Linked-Immunosorbent Assay (ELISA). A
control group of 41 age and sex matched healthy controls was also included.
Results: The mean level of 25-hydroxyvitamin D (30.65 ± 12.87 ng/ml) was signiﬁcantly
decreased in BD patients compared to the controls (37.98 ± 15.76 ng/ml) (p= 0.02). Signiﬁcant
negative correlations of serum vitamin D levels with patients’ ages (p= 0.03), ESR (p< 0.001),
CRP (p< 0.001) and BDCAF (p= 0.003) were found; whereas, there was no signiﬁcant correla-
tion with disease duration (p= 0.6). In multivariate regression analysis age (p= 0.02), colchicineartment of Rheumatology &
ital, Elqalyubia, Egypt, BO
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152 S.S Ganeb et al.therapy (0.008), ESR (0.02) and CRP (0.03) were found to be the independent effectors on vitamin
D serum levels.
Conclusion: Serum levels of vitamin D were signiﬁcantly lower in BD patients compared to con-
trols. Associations were found between vitamin D levels and age, BDCAF as well as ESR and CRP
in BD patients. Low vitamin D may predispose BD patients to active disease, especially in older
subjects.
 2013 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Behc¸et’s disease (BD) is a systemic relapsing chronic inﬂamma-
tory disease of unknown etiology that presents with recurrent
oral ulcers, genital ulcers, skin lesions and uveitis [1–3]. A wide
range of clinical features are observed, including involvement
of the ophthalmic, musculoskeletal, vascular, central nervous
and gastrointestinal systems [4].
The pathogenesis of BD includes Immune-mediated mech-
anisms and inﬂammatory mediators, hypersensitivity of T lym-
phocytes produced in response to different types of antigens
has a critical role in the pathogenic mechanisms [5–7].
Vitamin D has a major function in maintaining normal cal-
cium and phosphorus blood levels. The best measure of vita-
min D availability is serum levels of 25-hydroxyvitamin D [8]
which is the major circulating form, biologically inactive with
a half-life of about two weeks and reﬂects the amount of vita-
min D entering the circulation that proportionates to the
amount of vitamin D ingested and produced in the skin [9–
11]. It has major biologic activities including cellular prolifer-
ation and differentiation, immune system modulation and
muscle strengthening [12–15].
VitaminD is regarded as an environmental factor essential in
the etiology of T-cell-mediated autoimmune diseases [16]. Poor
vitamin D status is important in the initiation and propagation
of a range of autoimmune diseases [17] like multiple sclerosis,
type 1 diabetes, systemic lupus erythematosus, and rheumatoid
arthritis and is associated with an increased risk of several dis-
eases such as hypertension, infectious diseases, diabetes, cardio-
vascular disease, musculoskeletal disorders, asthma, as well as
several psychiatric conditions such as schizophrenia, depression,
and dementia and solid tumors [18–20]. Few studies have evalu-
ated serum levels of vitamin D in BD.
Some patients with autoimmune diseases have anti-vitaminD
antibodies while, several autoimmune pathways are suppressed
by vitamin D including the Th1, B cells, Th-17, dendritic cell,
and co-stimulatorymolecule systems [21]. VitaminDmetabolites
have direct targets to the adaptive immune system cells [22].
The aim of this study was to investigate serum levels of vita-
min D in patients with BD and to evaluate their relationship to
disease activity as well as different disease measures.
2. Patients and methods
2.1. Subjects
Forty-two BD patients diagnosed according to the Interna-
tional Study Group Criteria for BD (ISGC 1990) [23] and
forty-one age and sex matched healthy volunteers as control
group were included in this study. They were recruited fromthe inpatient and outpatient clinics of Rheumatology, Rehabil-
itation & Physical Medicine, General Medicine, Ophthalmol-
ogy and Dermatology & Andrology of Benha University
hospitals in the period between January 2010 and July 2010.
Patients were excluded from the study if they had other ill-
nesses that might affect the results of the study such as chronic
liver, kidney or endocrine disorders. Subjects taking medica-
tions known to inﬂuence calcium, vitamin D, or phosphorus
metabolism as anticoagulants; anticonvulsants; ﬂuoride; anti-
hypertensive drugs such as B-blockers, diuretics, and calcium
channel blockers were also excluded.
Informed written consents were obtained from all partici-
pants and the study was approved by the local Ethics
Committee.
2.2. Clinical assessments
All BD patients were subjected to the following:
- Detailed history taking
- Thorough clinical examination with stress on dermatologi-
cal, locomotor, vascular and ophthalmologic examination.
- Skin pathergy test was done [24].
- Weights and heights of all subjects were recorded, and body
mass index (BMI) was calculated as weight (kg)/height (m2).
- Assessment of disease activity according to Behc¸et’s Dis-
ease Current Activity Form (BDCAF) score [25].
2.3. Biochemical assessments
- Laboratory investigations: venous blood samples were
obtained from all patients and controls.
The following assessments were done:
- Complete blood picture by coulter counter.
- Erythrocyte sedimentation rate (ESR) by the Westergren
method recorded in mm/1st h.
- C-reactive protein (CRP) by standard nephelometry with
an established normal range of 0–0.8 mg/l.
- Total serum calcium (n= 8.1–10.4 mg/dl), total serum
phosphorus (n= 3.5–5 mg/dl) and total serum alkaline
phosphatase (n= 65–110 IU/L) were assessed spectropho-
tometrically on Hitachi 91.
- Total serum 25-hydroxyvitamin D (vitamin D) was assessed
by Enzyme -Linked- Immunosorbent Assay (ELISA). The
kit was derived from Immundiagnostik AG company had
a DIN IBO 9001 (2000) certiﬁcation (Australian).
Table 2 Clinical manifestations of BD patients.
Clinical manifestation Behc¸et’s disease patients (no = 42)
No (%)
Oral aphthous ulcers 32 (76.2)
Genital ulcers 8 (19.04)
Skin lesions 16 (38.1)
Arthritis 14 (33.33)
Ocular manifestations 16 (38.1)
Vascular lesions 4 (9.5)
Positive pathergy test 8 (19.04)
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cient, while levels of 30 ng/ml or less were considered low.
Statistical analysis: Statistical analysis was performed
using Statistical Package for Social Sciences software
(SPSS), version 13.0. Quantitative variables were presented
as the mean ± SD while qualitative data were expressed
as number and percent. Student‘s (t) test, Z, X2, Pearson’s
correlation coefﬁcient (r) and Mann Whitney U (MWU)
tests were used when appropriate. Multivariate regression
analysis was done to evaluate the effects of different vari-
ables on vitamin D levels. p Value less than 0.05 was con-
sidered signiﬁcant.3. Results
3.1. Demographic and BD related variables
- Patients’ characteristics are represented in (Table 1): The
mean disease duration was 9.77 ± 8.5 years. One patient
(2.4%) was on steroid use of 20 mg/d for the last two
months and 36 (85.7%) patients were on current colchicine
therapy (ranging between 1–1.5 mg/d), two of them were
taking low-dose steroids along with colchicine. Three
patients (7.1%) were on current calcium and vitamin D
supplementation. None of the patients was on bisphospho-
nate therapy.
- The mean BDCAF was 4.5 ± 2.9.
- Patients with BD presented with skin lesions as erytheman-
odosum, sterile pustules or papules in 16 patients (38.1%).
Arthritis was present in 14 patients (33.3%). Ocular disor-
ders [uveitis in 11 patients (26.2%), unilateral optic neuritis
in one patient (2.4%) and retinal vasculitis in one patient
(2.4%)] affected 13 patients (31%). Vascular lesions
[venous thrombosis in three patients (7.1%) and arterial
thrombosis in one patient (2.4%)] occurred in four patients
(9.5%) (Table 2).
- As regards inﬂammatory markers, both ESR and CRP
were signiﬁcantly higher in patients (26.43 ± 14.43 mm/
1st h) and (10.56 ± 8.87 mg/l) than controls (13.35 ±
5.74 mm/1st h) and (4.56 ± 3.57 mg/l), respectively
(Table 3).Table 1 Demographic and clinical data of BD patients and contro
Parameters Patien
Age (years) 35.72 ±
Male/female no 25/17
Disease duration (years) 9.77 ±
Weight (kg) 72.76 ±
Body mass index (kg/m2) 27.38 ±
Postmenopausal no (%) 1 (2.4)
Current calcium and vitamin D supplementation no (%) 3 (7.1)
Patients taking steroid, no (%) 3 (7.1)
Current Colchicine therapy no (%) 36 (85
Current Colchicine dose (mg/day) 1–1.5
Values are expressed as mean ± SD unless otherwise speciﬁed p> 0.05 =3.2. Vitamin D status in BD patients and controls
- There was a statistically signiﬁcant decrease in serum vita-
min D levels (p= 0.02) in patients (30.65 ± 12.87 ng/ml)
compared to controls (37.98 ± 15.76 ng/ml).
- There was a statistically signiﬁcant decrease (z= 2.16,
p= 0.03) of the median values and IQ ranges of serum
vitamin D levels between BD patients (29 and 22.75–39)
and controls (36 and 25.5–48.5), respectively.
- On comparison of serum vitamin D levels according to gen-
der in BD patients and control group, there were no signif-
icant differences of vitamin D levels according to gender in
BD patients [Males: 30.89 ± 11.87; Females: 29.685 ±
12.87 (t= 0.31, p= 0.76)], or in healthy controls
[Males: 38.76 ± 11.67; Females: 36.48 ± 11.65 (t= 0.62,
p= 0.54)].
- A statistically signiﬁcant decrease of vitamin D serum levels
was observed in BD patients with vascular lesions
(t= 3.72, p= 0.001), while there was an insigniﬁcant
decrease of serum vitamin D levels in patients with oral
ulcers (t= 1.5, p= 0.14), skin lesions (t= 0.5, p= 0.62),
arthritis (t= 0.55, p= 0.58), ocular lesions (t= 0.28,
p= 0.79) and positive skin Pathergy test (t= 0.82,
p= 0.42) (Table 4).
- In the group with sufﬁcient serum vitamin D levels, BD
patients had signiﬁcantly lower vitamin D levels compared
to controls (40.4 ± 6.9 ng/ml and 47.8 ± 12.5 ng/ml,
respectively, p= 0.03). In the group with low vitamin D,ls.
ts (no = 42) Controls(no = 41) T p
11.74 34.26 ± 10.82 0.59 0.56
23/18 0.1 0.75
8.5 – – –
14.43 76.67 ± 15.92 1.2 0.24
6.75 29.12 ± 6.96 1.2 0.25
– – –
– – –
– – –
.7) – – –
– – -
non signiﬁcant.
Table 3 Laboratory data of BD patients and control group.
Parameters Patients (no = 42) Controls (no = 41) T p
ESR (mm/1st hour) 26.43 ± 14.43 13.35 ± 5.74 5.4 0.000*
CRP (mg/l) 10.56 ± 8.87 4.56 ± 3.57 4.04 0.000*
Serum calcium (mg/dl) 8.25 ± 1.21 8.53 ± 1.23 1.1 0.27
P (mg/dl) 3.93 ± 1.92 4.19 ± 1.81 0.63 0.53
ALP (U/L) 98.54 ± 49.98 100.54 ± 50.45 0.18 0.86
Serum vitamin D (ng/ml) 30.65 ± 12.87 37.98 ± 15.76 2.3 0.02*
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, P: serum phosphorus, ALP: serum alkaline phosphatase.
* = signiﬁcant at p< 0.05, p> 0.05 = non signiﬁcant.
Table 4 Comparison between vitamin D serum levels in BD patients according to the presence and absence of different clinical
manifestations.
Clinical manifestation Vitamin D level (ng/ml) in BD patients (no = 42)
Presence Absence T p
Oral ulcers (no = 32) 29 ± 12.6 35.9 ± 12.7 1.500 0.141
Genital ulcers (no = 8) 31.9 ± 11.8 30.4 ± 13.3 0.297 0.768
Skin lesions (no = 16) 29.4 ± 10.5 31.4 ± 14.3 0.495 0.623
Arthritis (no = 14) 29.1 ± 10.9 31.4 ± 13.9 0.554 0.583
Ocular lesions (no = 16) 29.9 ± 11.1 31.1 ± 14 0.275 0.785
Vascular lesions (no = 4) 10.8 ± 3 32.7 ± 11.7 3.718 0.001*
+ve Pathergy (no = 8) 27.3 ± 11.5 31.4 ± 13.2 0.824 0.415
* = signiﬁcant at p< 0.05 p> 0.05 = non signiﬁcant.
154 S.S Ganeb et al.patients had also signiﬁcantly lower serum level of vitamin
D compared to the control group (19.6 ± 6.7 ng/ml and
24.2 ± 4.6 ng/ml, respectively, p= 0.034). Seventeen
patients (40.5%) and 28 of controls (68.3%) had sufﬁcient
vitamin D serum levels, while twenty-ﬁve patients (59.5)
and 13 of controls (31.7%) had low vitamin D levels and
the difference was statistically signiﬁcant (X2 = 6.5, p=
0.011) (Figure 1).
- -Comparison of some clinical and laboratory variables in
BD patients according to vitamin D levels revealed statisti-
cally signiﬁcant differences as regards age (t= 2.15,
p= 0.037) and BDCAF (t= 2.77, p= 0.008) (Table 5).
- -On correlating vitamin D serum levels with some variables
among controls, insigniﬁcant correlations were found with
age (r= 0.18, p= 0.27), ESR (r= 0.15, p= 0.36)
and CRP (r= 0.17, p= 0.28).Figure 1 Vitamin D serum levels in BD patients and controls.- -Signiﬁcant inverse correlations of serum vitamin D levels
with patients’ ages (r= 0.54, p= 0.03), ESR (r=
0.59, p< 0.001), CRP (r= 0.53, p< 0.001) (Table 6)
and BDCAF (r= 0.45, p= 0.003, Figure 2) were found.
Whereas, there was insigniﬁcant correlation of serum vita-
min D levels with disease duration (r= 0.1, p= 0.6).
3.3. Effectors of vitamin D levels in BD
- Multivariate regression analysis was performed to deter-
mine the main effectors of vitamin D levels. The variables
included age, disease duration, BDCAF, colchicine ther-
apy, ESR and CRP. Age (p= 0.02), colchicine therapy
(0.008), ESR (0.02) and CRP (0.03) were found to be the
independent effectors of vitamin D levels (Table 7).
4. Discussion
The etiopathogenesis of BD is still unclear, many factors have
been considered including: viral infection, autoimmune dis-
ease, streptococcal-related antigens and genetic factors,
[26,27].
Vitamin D has multiple immunosuppressant properties [20/
9]. Its importance could be explained by previous reports stat-
ing that it signiﬁcantly decreases the incidence and/or progres-
sion of autoimmune diseases [28,29].
This study aimed to investigate serum levels of vitamin D in
patients with BD and to evaluate their relationship to disease
activity as well as different disease measures.
Table 5 Comparison of some variables in BD patients according to vitamin D serum levels.
Variable BD patients (no = 42) according to vitamin D level Test value p
Suﬃcient (>30 ng/ml) (no = 17) Low (6 30 ng/ml) (no = 25)
Age (years) 32.8 ± 7.7 37.6 ± 6.5 t= 2.15 0.037*
Disease duration (years) 6.65 ± 4.56 9.83 ± 6.37 t= 1.76 0.09
Current smoker no (%) 1 (5.9) 6 (24) Z= 1.5 0.12
Current steroid no (%) 1 (5.9) 2 (8) Z= 0.26 0.79
Current Colchicine no (%) 13 (76.5) 23 (92) Z= 1.4 0.15
BDCAF 3.1 ± 2.3 5.4 ± 2.9 t= 2.77 0.008*
Values are expressed as mean ± SD unless otherwise speciﬁed.
BDCAF: Behc¸et’s Disease Current Activity Form.
* Signiﬁcant at p< 0.05 p> 0.05 = non signiﬁcant.
Table 6 Correlations between vitamin D serum levels and
variables in BD patients.
Variable R p-value
Age (years) 0.54 0.03*
Disease duration (years) 0.1 0.6
BDCAF 0.45 0.003*
ESR (mm/1st hour) 0.59 0.000*
CRP (mg/l) 0.53 0.000*
ESR: erythrocyte sedimentation rate, CRP: C- reactive protein,
BDCAF: Behc¸et’s Disease Current Activity Form.
* Signiﬁcant at p< 0.05 p> 0.05 = non signiﬁcant.
Figure 2 Correlations of serum vitamin D levels with patients’
Behc¸et’s Disease Current Activity Form (BDCAF).
Table 7 Multivariate regression analysis in BD patients.
Beta p
Age (years) 0.67 0.02*
Disease duration (years) 0.03 0.86
Colchicine therapy 0.86 0.008*
ESR (mm/1st hour) 0.37 0.02*
CRP (mg/L) 0.31 0.03*
BDCAF 0.17 0.21
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein,
BDCAF: Behc¸et’s Disease Current Activity Form.
* = signiﬁcant at p< 0.05 p> 0.05 = non signiﬁcant.
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vitamin D were signiﬁcantly decreased (p= 0.02) in BD pa-
tients compared to healthy controls. Seventeen patients
(40.5%) and 28 of controls (68.3%) had sufﬁcient vitamin D
serum levels, while 25 patients (59.5%) and 13 of controls
(31.7%) had low vitamin D levels and the difference was statis-
tically signiﬁcant (p= 0.011). Decreased serum levels of vita-
min D have been reported in BD [30] and several other
autoimmune diseases including rheumatoid arthritis [16,31],
systemic lupus erythematosus [17,32], multiple sclerosis [33]
and undifferentiated connective tissue disease [34]. Those stud-
ies suggested that down-regulation of vitamin D is almost in-
volved in the pathogenesis of these diseases.
Colin et al. [31] stated that vitamin D and vitamin D
analogs’ supplementation contribute to the bone-preserving
effects and could have a role when combined with corticoste-roids in the prevention of focal bone erosions in RA. They also
reported that these ﬁndings may be effective for other chronic
inﬂammatory autoimmune diseases treated with corticoste-
roids.
Several factors decrease vitamin D levels. Reduced skin
synthesis and absorption of vitamin D occur with the aging
process [32], obesity results in vitamin D sequestration in body
fat [35], smoking impairs 1-alpha-hydroxylation [36] and en-
hances hepatic degradation of estrogen which alters metabo-
lism of vitamin D [37], corticosteroids accelerate vitamin D
catabolism [38] and estrogen deﬁciency increases parathor-
mone hormone leading to decreased vitamin D [39].
This study revealed a statistically signiﬁcant decrease of
vitamin D serum levels in BD patients with vascular lesions
compared to those patients without vascular lesions (p=
0.001). This conﬁrmed previous studies that found vitamin D
deﬁciency to be associated with cardiovascular events such as
myocardial infarction or stroke [40,41].
We found a signiﬁcant negative association between vita-
min D serum levels and patients’ ages (p= 0.03). Several pre-
vious studies found a negative correlation between vitamin D
serum levels and patients’ age [42–45]. Lerner et al. [21] re-
ported that age is the major factor affecting serum vitamin
D levels. Yu et al. [46] stated that in aged BD patients, calcium
status of the host may inﬂuence the effect of vitamin D on
immunity.
In the present study, there were signiﬁcant negative correla-
tions of vitamin D serum levels with BD patients’ ESR
(p< 0.001) and CRP (p< 0.001). These ﬁndings were in agree-
ment with those of Do et al. [30] who found decreased serum
vitamin D levels were inversely correlated with ESR and CRP
levels. On the other hand Karaty et al. [47] demonstrated that
156 S.S Ganeb et al.there was no correlation between vitamin D levels and ESR or
CRP levels in BD patients. Timms et al. [48], in their study on
healthy adults revealed that CRP levels were decreased by
23% in hypovitaminosis Dpatients who received approximately
547 IU of vitamin D daily for 2.5 years and suggested a dose-
dependent anti-inﬂammatory effect of vitamin D.
The results of this study exhibited signiﬁcant negative
correlations of vitamin D serum levels with BDCAF (p=
0.003). Our results go hand in hand with those of Do et al.
[30] who showed decreased serum vitamin D levels in active
BD patients compared with controls and suggested that vita-
min D deﬁciency is a possible risk factor for BD activity and
disturbance in the inﬂammatory condition. In the same con-
text, Hamzaoui and his colleagues [49] found that in active
BD patients, there were signiﬁcantly inverse correlations be-
tween vitamin D levels and both CRP and ESR expression,
indicating that disease activity is associated with lower vitamin
D serum levels while, no correlations were observed in healthy
controls and inactive BD patients. They also observed a signif-
icant and inverse correlation between vitamin D of active BD
patients and age.
Dusso et al. [50] reported that a low vitamin D level is pos-
sibly an indicator for the inﬂammatory process as Inﬂamma-
tion itself potentially enhances vitamin D catabolism.
In multivariate regression analysis, age (p= 0.02), colchi-
cine therapy, (0.008), ESR (0.02) and CRP (0.03) were found
to be independent effectors of vitamin D levels.
Karatay and his associates [47], in multivariate regression
analysis, stated that smoking, alcohol intake, and use of col-
chicine were the main predictors of vitamin D levels, although
the effects of colchicine on vitamin D levels have not yet been
fully deﬁned.
In conclusion, this study demonstrated that serum levels of
vitamin D were signiﬁcantly lower in BD patients compared to
controls. Associations were found between vitamin D levels
and age, disease activity as well as ESR and CRP in BD pa-
tients. Low vitamin D may predispose those patients to active
disease, especially in older subjects. More studies are required
to determine whether treatment with vitamin D would have
beneﬁcial effects on patients with BD.
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